H. Lundbeck A/S and Myriad Genetics, Inc. today announced that Lundbeck has acquired European commercialization rights to Myriad's Flurizan® (tarenflurbil). Flurizan® might have the potential to delay disability in patients suffering from Alzheimer's disease. Myriad and Lundbeck have entered into...